Large cystic intraparenchymal brain metastasis from prostate cancer

1992 ◽  
Vol 34 (1) ◽  
pp. 70-72 ◽  
Author(s):  
L. I. Bland ◽  
W. C. Welch ◽  
S. -H. Okawara
Keyword(s):  
Prostate Cancer ◽  
Brain Metastasis

Brain Metastasis as a Sole Recurrence of Prostate Cancer after Total Prostatectomy

1998 ◽  
Vol 60 (2) ◽  
pp. 121-123 ◽  
Author(s):  
Tetsuo Hayashi ◽  
Kazumasa Igarashi ◽  
Akiko Tanizawa ◽  
Yoko Terada ◽  
Hideaki Sekine
Keyword(s):  
Prostate Cancer ◽  
Brain Metastasis ◽  
Total Prostatectomy

SUBDURAL HEMATOMA SECONDARY TO BRAIN METASTASIS IN A PROSTATE CANCER: A CADAVERIC FINDING

2016 ◽  
Vol 4 (3.2) ◽  
pp. 2643-2645
Author(s):  
Amruta Rajput ◽  
◽  
Yamah Ahad Naim ◽  
Varun Kumar Ranu ◽  
Lakshmi Gopinath Jaisankar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Brain Metastasis ◽  
Subdural Hematoma

Clinical, genetic, and pathologic determinants of prostate cancer brain metastasis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 5536-5536
Author(s):  
Mira Patel ◽  
N. Ari Wijetunga ◽  
Stephanie Lobaugh ◽  
Zhigang Zhang ◽  
Sean Matthew McBride ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Brain Metastasis ◽  
Fanconi Anemia ◽  
Impact Analysis ◽  
Rare Event ◽  
Genetic Profile ◽  
Ras Signaling ◽  
Node Positive ◽  
T Stage ◽  
Node Positive Disease

5536 Background: Prostate cancer (PCa) brain metastasis (BM) is a rare event occurring in 0.16-0.63% of PCa patients. Current clinical data on this phenomenon is limited to small retrospective cohorts and our understanding of it is incomplete. We sought to identify clinical and molecular predictors of PCa BM in a large retrospective cohort treated at our institution. Methods: Men diagnosed with Pca from 1995-2017 with ≥6 months of follow-up were included. Data was collected on clinical and tumor characteristics at diagnosis, PCa treatment, brain and bone metastasis, and tumor genetic profile based on Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) analysis. Results were examined using Kyoto Encyclopedia of Genes and Genome (KEGG) pathway. Genes altered in ≥5% of patients were included. Time to brain metastasis (TTBM) and overall survival (OS) were analyzed with univariable (UVA) Fine-Gray competing risks regression and Cox proportional hazards. TTBM and OS were landmarked at 6 months after PCa diagnosis. False discovery rate (FDR) adjustment accounted for multiple comparisons. Results: 27,887 men met inclusion criteria; 74 developed BM. Clinical variables associated with increased hazard of TTBM in UVA were high-clinical and pathologic-* (p<.001) T stage, node-positive disease* (p<.001), primary* and total* Gleason (p<.001), receipt of abiraterone* (HR 52.51 (95% CI 7.1-389.8), p<.001), and receipt of leuprolide* (HR 3.0 (95% CI 1.7-5.4), p<.001). Tumor alterations associated with BM include mutations in BRCA2 (HR 2.94 (95% CI 1.1-8.0), p=.04), MYC (HR 3.41 (95% CI 1.2-9.5), p=.02), PTEN (HR 2.90 (95% CI 1.2-6.9), p=.02), RB1 (HR 3.09 (95% CI 1.2-8.0), p=.02), and pathways involving homologous recombination (HR 2.70 (95% CI 1.1-6.4), p=.02), Fanconi anemia* (HR 4.22 (95% CI 1.8-10.0), p<.001), Ras signaling* (HR 4.6 (95% CI 1.5-13.9), p=.006), mTOR signaling (HR 2.88 (95% CI 1.1-7.9), p=.04), VEGF signaling* (HR 3.60 (95% CI 1.5-8.8), p=.005), and GnRH signaling* genes (HR 3.93 (95% CI 1.6-9.6), p0.003). Variables associated with increased hazard of BM after FDR adjustment are denoted with an asterisk. Variables associated with reduced OS after FDR adjustment were neuroendocrine or blastoma histology, node-positive disease, high-T stage, high initial PSA, receipt of leuprolide, and alterations in AR, TP53, and CDK12 genes. Conclusions: PCa BM is significantly associated with high-stage and grade disease, receipt of androgen deprivation agents such as abiraterone and leuprolide, and alterations in the Fanconi anemia, Ras, VEGF, and GnRH pathways.

Solitary brain metastasis from prostate cancer: a case report

2016 ◽  
Vol 5 (3) ◽  
pp. 227-232 ◽  
Author(s):  
Tasneem Barakat ◽  
Arnav Agarwal ◽  
Rachel McDonald ◽  
Vithusha Ganesh ◽  
Sherlyn Vuong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Brain Metastasis ◽  
Solitary Brain Metastasis

scholarly journals The dialyzable leukocyte extract TransferonTM inhibits tumor growth and brain metastasis in a murine model of prostate cancer

2018 ◽  
Vol 101 ◽  
pp. 938-944 ◽  
Author(s):  
Miguel A. Hernández-Esquivel ◽  
Armando Pérez-Torres ◽  
Laura Romero-Romero ◽  
Alonso Reyes-Matute ◽  
Brenda Loaiza ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Brain Metastasis ◽  
Tumor Growth ◽  
Murine Model

scholarly journals Brain metastasis from prostate cancer: A review of the literature with an illustrative case

2021 ◽  
Vol 37 ◽  
pp. 100419
Author(s):  
Mohammed Maan Al-Salihi ◽  
Maryam Sabah Al-Jebur ◽  
Ivan David Lozada-Martinez ◽  
Md Moshiur Rahman ◽  
Sabrina Rahman
Keyword(s):  
Prostate Cancer ◽  
Brain Metastasis ◽  
Illustrative Case ◽  
Review Of The Literature

IDH1 mutation in prostate cancer: R132H and beyond.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 213-213 ◽  
Author(s):  
Amber Lea Flaherty ◽  
Jamie Teer ◽  
Jingsong Zhang
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Amino Acid ◽  
Brain Metastasis ◽  
Allele Frequency ◽  
Amino Acid Change ◽  
1000 Genomes ◽  
Primary Prostate Cancer ◽  
Treatment Naïve ◽  
Prostate Cancers

213 Background: Previous reports on mutations in the isocitrate dehydrogenase 1 (IDH1) gene in prostate cancer focused on the evolutionarily conserved residue R132 located in the substrate binding site of IDH1. One study reported R132 mutations in 2/75 (2.7%) prostate cancers, whereas the other study did not find R132 mutation in 4 prostate cancers. We therefore studied the IDH1 mutations in our prostate cancer targeted exon sequencing database. Methods: Targeted exon sequencing was performed on 52 treatment naïve prostate cancers as part of Moffitt Cancer Center’s Total Cancer Care initiative. The coverage was set to be at least 50 fold. 51/52 samples are primary prostate cancer obtained during radical prostatectomy and 1 sample is a brain metastasis. The 1000 Genomes and the NHLBI Exome Sequencing Project (ESP) were used to exclude likely polymorphisms. The catalogue of somatic mutations in cancer (COSMIC) was used to identify mutations seen in other sequencing projects, and Polyphen2 was used to predict the potential detrimental effect of the amino acid changes predicted from the genetic mutations. Results: 1/51 (2%) primary prostate cancers harbor the R132H mutation, which is known to generate the oncometabolite, (R)-2-hydroxylutarate. Y183C was identified in 1/51 samples. This amino acid change in exon 6 of IDH1 is seen at 1% allele frequency in 1000 Genomes and ESP-euro. It is classified as "probably_damaging" with a PolyPhen2 score of .999. Another "probably_damaging" amino acid change is T325M mutation, which is identified in a different primary prostate cancer. V178I in IDH1 was also identified and is thought to be an inherited variant, given it has an allele frequency of 4% in 1000 Genomes, 5% in ESP-european, and 8% in ESP-African-American. Among the frequent gene mutations in metastatic prostate cancer, only a missense mutation in the androgen receptor (H875Y) was identified in the treatment naïve brain metastasis. This H875Y has been linked to promiscuous androgen receptor. Conclusions: Mutations in IDH1 R132H and other “probably_damaging” amino acid changes are identified in primary prostate cancers. This holds further implications for future studies on prostate cancer, and may point to an interesting target in the disease.

Prostate cancer brain metastasis in a contemporary cohort.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e14011-e14011
Author(s):  
Paul Brittain ◽  
Derek Smith ◽  
Dexiang Gao ◽  
Elizabeth Riley Kessler ◽  
Brandon David Bernard ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Brain Metastasis

scholarly journals A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation

2019 ◽  
Vol 69 (12) ◽  
pp. 715-720 ◽  
Author(s):  
Takeo Kosaka ◽  
Hiroshi Hongo ◽  
Eriko Aimono ◽  
Kazuhiro Matsumoto ◽  
Tetsu Hayashida ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Brain Metastasis ◽  
Brca2 Mutation ◽  
Japanese Case ◽  
Neuroendocrine Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document